Baxter International Inc
NYSE:BAX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.7
43.77
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BAX stock under the Base Case scenario is 65.62 USD. Compared to the current market price of 33.21 USD, Baxter International Inc is Undervalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Baxter International Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BAX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Baxter International Inc. is a global healthcare company that has been a trusted name in the medical sector for over eight decades. Founded in 1931, Baxter specializes in lifesaving medical products and therapies, primarily focusing on renal and hospital care. The company's innovations have revolutionized treatment protocols for conditions such as kidney failure, where their dialysis products are vital for patient care. Additionally, Baxter manufactures a diverse range of infusion systems, biosurgery products, and medications, playing a crucial role in surgical and medical environments. With a commitment to improving patient outcomes, Baxter invests heavily in research and development, which...
Baxter International Inc. is a global healthcare company that has been a trusted name in the medical sector for over eight decades. Founded in 1931, Baxter specializes in lifesaving medical products and therapies, primarily focusing on renal and hospital care. The company's innovations have revolutionized treatment protocols for conditions such as kidney failure, where their dialysis products are vital for patient care. Additionally, Baxter manufactures a diverse range of infusion systems, biosurgery products, and medications, playing a crucial role in surgical and medical environments. With a commitment to improving patient outcomes, Baxter invests heavily in research and development, which positions it well for future growth, particularly as global healthcare needs continue to expand.
As an investor, understanding Baxter’s strategic position in the healthcare industry is key. The company enjoys a robust financial footing, bolstered by its extensive product portfolio and a global distribution network that spans over 100 countries. Recently, Baxter has focused on enhancing its operational efficiency and pursuing strategic acquisitions to broaden its product offerings and enter emerging markets. Moreover, as healthcare systems worldwide prioritize chronic disease management, Baxter’s innovative solutions are increasingly in demand, reinforcing its potential for sustainable revenue growth. In an ever-evolving healthcare landscape, Baxter International Inc. stands out as a formidable player, driven by a mission to save and sustain lives, making it an attractive option for long-term investors looking to enter the healthcare sector.
Baxter International Inc. is a global healthcare company that focuses on developing, manufacturing, and distributing a wide range of medical products and services. The company's core business segments typically include:
-
Hospital Products: This segment encompasses a variety of intravenous (IV) solutions, parenteral nutrition products, and infusion systems. These products are crucial for the treatment of patients in hospital settings, especially those requiring fluid management, a key component of patient care.
-
Renal Care: Baxter is a leader in therapies for treating patients with kidney disease. This segment includes products for both dialysis treatment and home-based renal therapies. The company provides hemodialysis and peritoneal dialysis solutions, along with related equipment and services, which are essential for patients with chronic kidney conditions.
-
Pharmaceuticals: This segment involves the production of injectable medications, including anesthetics, analgesics, and other critical-care medications. Baxter’s pharmaceutical products are often used in acute care settings, surgical procedures, and for the treatment of various medical conditions.
-
Advanced Surgery: Baxter produces products used in surgical procedures, particularly those that focus on hemostasis and sealing. This includes surgical hemostats and tissue sealants, which are designed to minimize bleeding during surgeries.
-
Baxter’s BioScience Segment: Although not always listed as a separate segment in all reports, Baxter also develops biologic therapies for conditions such as hemophilia and immune deficiencies. This includes a range of biologic products made from human plasma.
Each of these segments plays a crucial role in Baxter's overall mission to save and sustain lives through innovative medical solutions. The company continues to invest in research and development to advance its product offerings and improve patient outcomes across these key areas.
Baxter International Inc. possesses several unique competitive advantages that help it stand out in the healthcare industry, especially in the areas of pharmaceuticals and medical devices:
-
Strong Portfolio of Products: Baxter has a diverse range of products in various therapeutic areas, including renal care, medication delivery, and surgical products. This broad product portfolio provides a competitive edge by meeting a wide array of patient needs.
-
Innovation and R&D: Baxter invests heavily in research and development to drive innovation in its products. The company has a strong pipeline of new products and technologies that can enhance patient care and improve treatment outcomes.
-
Established Brand Reputation: With over 90 years in the healthcare industry, Baxter has built a strong brand recognized for quality and reliability. Trust in the brand can lead to customer loyalty and retention, giving it an advantage over competitors.
-
Global Reach and Scale: Baxter operates in more than 100 countries, which allows it to leverage economies of scale in manufacturing and distribution. This global presence provides an advantage in sourcing materials, understanding diverse market needs, and delivering products effectively.
-
Strong Regulatory Knowledge and Experience: The company has extensive experience navigating complex regulatory environments in various countries. This expertise helps Baxter efficiently bring products to market, ensuring compliance and reducing the time it takes to gain approvals.
-
Strategic Partnerships and Collaborations: Baxter often collaborates with other healthcare providers, technology companies, and research institutions, which enhances its innovation capabilities and market reach.
-
Focus on Patient-Centric Solutions: Baxter emphasizes the development of solutions tailored to patient needs, which differentiates it from competitors. By prioritizing patient outcomes, the company can build stronger relationships with healthcare providers and patients alike.
-
Operational Efficiency: Baxter employs advanced manufacturing processes and technologies that improve operational efficiency and reduce costs. This efficiency can lead to better pricing strategies compared to less efficient competitors.
-
Commitment to Sustainability: Baxter has made strides in sustainability and corporate responsibility, which can resonate with healthcare providers and consumers increasingly focused on ethical and sustainable practices.
-
Strong Financial Position: Baxter's solid financial foundation allows it to invest in growth opportunities, navigate downturns, and weather competitive pressures better than some of its rivals.
These advantages work synergistically to strengthen Baxter International's position in the market, enabling it to compete effectively and adapt to changing healthcare demands.
Baxter International Inc., a global healthcare company focusing on renal and hospital products, faces several risks and challenges in the near future:
-
Regulatory Challenges: The healthcare industry is heavily regulated. Changes in regulations, such as those from the FDA and other global regulatory bodies, can impact product approvals and market access. Ensuring compliance can also increase operating costs.
-
Competition: Baxter operates in a competitive environment with numerous players in the renal, drug delivery, and hospital product spaces. Innovation and pricing pressure from competitors can affect market share and profit margins.
-
Supply Chain Disruptions: Global supply chain issues, whether due to geopolitical tensions, natural disasters, or pandemics, can lead to shortages of raw materials and manufactured products, affecting production and sales.
-
Market Access and Reimbursement Issues: Changes in healthcare policies, especially in the U.S. and in key international markets, can impact reimbursement rates and access to products. This can reduce profitability and market penetration for Baxter's products.
-
Technological Changes: Rapid advancements in medical technology could render existing products obsolete. Baxter must continuously innovate to keep pace and invest in R&D to develop new products and solutions.
-
Economic Uncertainty: Economic downturns can lead to reduced healthcare spending, affecting sales of Baxter's products. Additionally, inflation can increase costs and squeeze margins.
-
Litigation Risks: Like many healthcare companies, Baxter may face patent disputes and product liability lawsuits, which can lead to financial liabilities and reputational damage.
-
Global Health Issues: The ongoing implications of the COVID-19 pandemic and potential future health crises could disrupt operations, change demand dynamics, and strain healthcare systems.
-
Workforce Challenges: Attracting and retaining qualified talent, especially in a competitive job market, poses a challenge. Employee turnover and labor shortages can impact operations and innovation.
-
Environmental, Social, and Governance (ESG) Factors: Increasing scrutiny on healthcare companies regarding their ESG practices can pose reputational risks. Companies that fail to address sustainability and ethical concerns may face backlash from investors and customers.
By understanding and preparing for these risks, Baxter can better position itself for future success and resilience.
Revenue & Expenses Breakdown
Baxter International Inc
Balance Sheet Decomposition
Baxter International Inc
Current Assets | 8.6B |
Cash & Short-Term Investments | 2.1B |
Receivables | 2.7B |
Other Current Assets | 3.8B |
Non-Current Assets | 17.7B |
PP&E | 4.8B |
Intangibles | 11.7B |
Other Non-Current Assets | 1.1B |
Current Liabilities | 6.1B |
Accounts Payable | 1.3B |
Accrued Liabilities | 2.3B |
Other Current Liabilities | 2.6B |
Non-Current Liabilities | 12.5B |
Long-Term Debt | 10.4B |
Other Non-Current Liabilities | 2.1B |
Earnings Waterfall
Baxter International Inc
Revenue
|
14B
USD
|
Cost of Revenue
|
-8.6B
USD
|
Gross Profit
|
5.4B
USD
|
Operating Expenses
|
-4.9B
USD
|
Operating Income
|
449m
USD
|
Other Expenses
|
-341m
USD
|
Net Income
|
108m
USD
|
Free Cash Flow Analysis
Baxter International Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Baxter reported a 4% increase in sales to $3.85 billion, outperforming expectations, driven by strong performance in Medical Products & Therapies, particularly with a 7% growth in infusion therapies. Adjusted earnings per share rose 18% to $0.80, exceeding guidance. However, Hurricane Helene is expected to negatively impact Q4 sales by about $200 million, affecting overall 2024 sales growth guidance to 1% to 2%. For continuing operations, Baxter anticipates 2% growth. Looking forward, the company expects 2025 sales growth to return to 4% to 5% and operating margins of 16.5%, aided by improved operational efficiencies.
What is Earnings Call?
BAX Profitability Score
Profitability Due Diligence
Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
BAX Solvency Score
Solvency Due Diligence
Baxter International Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Baxter International Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAX Price Targets Summary
Baxter International Inc
According to Wall Street analysts, the average 1-year price target for BAX is 38.59 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.
Dividends
Current shareholder yield for BAX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BAX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. The company is headquartered in Deerfield, Illinois and currently employs 60,000 full-time employees. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
Contact
IPO
Employees
Officers
The intrinsic value of one BAX stock under the Base Case scenario is 65.62 USD.
Compared to the current market price of 33.21 USD, Baxter International Inc is Undervalued by 49%.